Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension

Stanford University, Stanford, California.
The American journal of cardiology (Impact Factor: 3.43). 07/2012; 110(10). DOI: 10.1016/j.amjcard.2012.07.012
Source: PubMed

ABSTRACT Pulmonary arterial hypertension (PAH) is a disease characterized by increased pulmonary pressures and chronic right heart failure. Therapies for moderate and severe PAH include subcutaneous (SQ) and intravenous (IV) prostanoids that improve symptoms and quality of life. However, treatment compliance can be limited by severe side effects and complications related to methods of drug administration. Inhaled prostanoids, which offer the advantage of direct delivery of the drug to the pulmonary circulation without need for invasive approaches, may serve as an alternative for patients unable to tolerate SQ/IV therapy. In this retrospective cohort study we collected clinical, hemodynamic, and functional data from 18 clinically stable patients with World Health Organization group I PAH seen in 6 large national PAH centers before and after transitioning to inhaled treprostinil from IV/SQ prostanoids. Before transition 15 patients had been receiving IV or SQ treprostinil (mean dose 73 ng/kg/min) and 3 patients had been on IV epoprostenol (mean dose 10 ng/kg/min) for an average duration of 113 ± 80 months. Although most patients who transitioned to inhaled treprostinil demonstrated no statistically significant worsening of hemodynamics or 6-minute walk distance, a minority demonstrated worsening of New York Heart Association functional class over a 7-month period. In conclusion, although transition of patients from IV/SQ prostanoids to inhaled treprostinil appears to be well tolerated in clinically stable patients, they should remain closely monitored for signs of clinical decompensation.

Download full-text


Available from: Robert C Bourge, Jul 29, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE OF REVIEW: Pulmonary arterial hypertension (PAH) is a complex disease with a high mortality. Management of this disease is underpinned by supportive and general therapies delivered by multidisciplinary teams in specialist centres. In recent years, a number of PAH-specific therapies have improved patient outcomes. This article will discuss the management of PAH in the context of relevant recently published studies in this area. RECENT FINDINGS: PAH-specific therapies are targeted towards dysfunctional signalling identified within the pulmonary circulation, and include endothelin receptor antagonists, phosphodiesterase type-5 inhibitors and prostanoids. Combination of these therapies is considered in patients with more severe disease. In addition, timely referral for surgical intervention (e.g. atrial septostomy, lung transplantation) should be made in selected patients with advanced disease. New treatment modalities currently in development may further improve patient outcomes in future years. However, further development and expansion of patient registries is vital for enhanced understanding of this disease, and may guide the optimal use of existing therapies and the development of new treatment approaches. SUMMARY: Outcomes in PAH have improved in recent years through a management approach characterized by general and supportive measures, and PAH-specific and surgical therapies in selected patients. Continued development of patient registries is vital to improve understanding and outcomes of this disease.
    Current opinion in critical care 12/2012; DOI:10.1097/MCC.0b013e32835c5137 · 3.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Treprostinil is a synthetic prostacyclin analogue with antiplatelet and vasodilatory properties. It is the only prostacyclin analogue with different options of delivery, i.e. subcutaneous, intravenous, inhaled or oral. Subcutaneous treprostinil has been shown in short- and long-term studies to improve exercise capacity, functional class, haemodynamics and survival in patients with pulmonary arterial hypertension (PAH). Pain at the infusion site has been a major drawback of subcutaneous treprostinil, hampering dose titration, and ultimately leading to increased discontinuation rates. The additional clinical interest in treprostinil as an alternative intravenous prostacyclin has developed due to its favourable properties, including longer half-life, chemical stability, the possibility of intravenous infusion without the need for ice packs, and easy drug preparation. Intravenous treprostinil improves exercise capacity, functional class and haemodynamics in patients with PAH, over the period of 12 weeks. If patients are switched to intravenous treprostinil, they usually need to double the dose to attain the same efficacy. Whether the effect of intravenous treprostinil remains clinically relevant beyond 12 weeks is not known, and a longer follow-up would be required to investigate this. Inhaled treprostinil is an efficacious treatment in PAH patients who are moderately symptomatic on background oral therapy. Oral treprostinil on top of background therapy did not lead to an improvement in 6-minute walking distance after 16 weeks of treatment.
    Drugs 12/2012; 72(18):2351-63. DOI:10.2165/11638260-000000000-00000 · 4.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prostacyclins have a favourable pharmacological profile for treatment of pulmonary hypertension as they possess vasodilative, antiproliferative, antiaggregatory, and anti-inflammatory properties that may compensate the main pathologic changes in the small pulmonary arteries. In severe pulmonary hypertension these vessels show a deficit in the endogenous prostacyclin secretion. The therapeutic potential of prostacyclin for pulmonary hypertension has been known since 30 years, and since nearly 20 years prostacyclin has been approved for idiopathic PAH. There are intravenous, subcutaneous, and inhaled approaches of different substances who share many but not all pharmacologic properties. However, none of these approaches are easy and free of adverse effects. Long-term experience and careful decision-making are instrumental to achieve favourable clinical long-term results.
    Handbook of experimental pharmacology 01/2013; 218:177-198. DOI:10.1007/978-3-642-38664-0_8
Show more